Showing 1 posts of 1 posts found.
New Phase 3 data has been released on Johnson & Johnson’s selective sphingosine-1-phosphate receptor 1 (S1P1) modulator ponesimod, reporting that …
Product value to pathway impact: What the CVD Modern Service Framework means for pharma
MHRA awards Innovation Passports to liver cancer and dementia medicines
Scottish NHS hospital adopts light-activated therapy to reduce surgical infections
Manchester launches nurse-led clinic to improve kidney transplant outcomes
Androlabs and Majorelle expand testosterone therapy into France